{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Trelegy+Ellipta",
    "query": {
      "intervention": "Trelegy Ellipta"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 7,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T13:28:54.112Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03949842",
      "title": "Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone furoate/umeclidinium/vilanterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2019-06-27",
      "completion_date": "2022-11-30",
      "has_results": false,
      "last_update_posted_date": "2020-04-22",
      "last_synced_at": "2026-09-02T13:28:54.112Z",
      "location_count": 3,
      "location_summary": "Waterbury, Connecticut • Charlotte, North Carolina • Layton, Utah",
      "locations": [
        {
          "city": "Waterbury",
          "state": "Connecticut"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Layton",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03949842"
    },
    {
      "nct_id": "NCT05757102",
      "title": "A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "FF/UMEC/VI",
          "type": "DRUG"
        },
        {
          "name": "ELLIPTA",
          "type": "DEVICE"
        },
        {
          "name": "FF/VI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 292,
      "start_date": "2023-04-25",
      "completion_date": "2027-01-28",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-09-02T13:28:54.112Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Paradise Valley, Arizona + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Paradise Valley",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05757102"
    },
    {
      "nct_id": "NCT05292053",
      "title": "Outcomes of Once-Daily ICS/LABA/LAMA + PRN Respiratory Therapy Treatments in Hospitalized Patients With COPD Exacerbations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Copd"
      ],
      "interventions": [
        {
          "name": "TRELEGY ELLIPTA 100Mcg-62.5Mcg-25Mcg/Actuation Powder for Inhalation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2022-07-01",
      "completion_date": "2025-02-09",
      "has_results": true,
      "last_update_posted_date": "2025-11-21",
      "last_synced_at": "2026-09-02T13:28:54.112Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05292053"
    },
    {
      "nct_id": "NCT05169424",
      "title": "A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Trelegy Ellipta",
          "type": "DEVICE"
        },
        {
          "name": "Stiolto Respimat",
          "type": "DEVICE"
        },
        {
          "name": "Tiotropium + Olodaterol (5/5 mcg)",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 9117,
      "start_date": "2021-12-17",
      "completion_date": "2021-12-27",
      "has_results": true,
      "last_update_posted_date": "2023-10-19",
      "last_synced_at": "2026-09-02T13:28:54.112Z",
      "location_count": 1,
      "location_summary": "White Plains, New York",
      "locations": [
        {
          "city": "White Plains",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05169424"
    },
    {
      "nct_id": "NCT07282886",
      "title": "VENTURI (VENTilation Using Respiratory Imaging)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 20,
      "start_date": "2026-03-15",
      "completion_date": "2030-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-09-02T13:28:54.112Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07282886"
    },
    {
      "nct_id": "NCT05127304",
      "title": "A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Trelegy Ellipta",
          "type": "DEVICE"
        },
        {
          "name": "Stiolto Respimat",
          "type": "DEVICE"
        },
        {
          "name": "Furoate/Umeclidinium/Vilanterol",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium Bromide/Olodaterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 11316,
      "start_date": "2021-02-26",
      "completion_date": "2022-02-03",
      "has_results": true,
      "last_update_posted_date": "2023-11-13",
      "last_synced_at": "2026-09-02T13:28:54.112Z",
      "location_count": 1,
      "location_summary": "Eden Prairie, Minnesota",
      "locations": [
        {
          "city": "Eden Prairie",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05127304"
    },
    {
      "nct_id": "NCT04606394",
      "title": "Peak Inspiratory Flow and Dry Powder Inhaler Performance in COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "Trelegy Ellipta 100/62.5/25Mcg Inh 30D",
          "type": "DRUG"
        },
        {
          "name": "Ventolin 90Mcg/Actuation Inhalation Aerosol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pulmonary Research Institute of Southeast Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2020-12-02",
      "completion_date": "2021-12-15",
      "has_results": true,
      "last_update_posted_date": "2023-05-08",
      "last_synced_at": "2026-09-02T13:28:54.112Z",
      "location_count": 1,
      "location_summary": "Farmington Hills, Michigan",
      "locations": [
        {
          "city": "Farmington Hills",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04606394"
    }
  ]
}